 |
Clinical Trials for Cancer |
 |
|
 Breast Cancer Clinical Trial |
|
|
 |
Breast Cancer Clinical Trial |
|
|
|
Breast Cancer Clinical Trial |
|
|
A Randomized, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (LPT112515)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Breast Cancer Clinical Trial |
|
|
A randomized double-blind, placebo-controlled study of everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole (CRAD001Y2301)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Breast Cancer Clinical Trial |
|
|
|
Breast Cancer Clinical Trial |
|
|
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3
Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) (20060359)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
|
|
|
|
|
Colorectal Cancer (CRC) Clinical Trial |
|
|
|
Colorectal Cancer (CRC) Clinical Trial |
|
|
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as a Second-line Treatment in Subject with Metastatic Colorectal Cancer w/ Kras (Amgen 20060141 SPIRITT)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
|
|
|
|
|
Hepatocellular Carcinoma (HCC) Clinical Trial |
|
|
|
Hepatocellular Carcinoma (HCC) Clinical Trial |
|
|
|
|
|
|
|
|
Lung Cancer - Non Small Cell (NSCLC) Clinical Trial |
|
|
|
Lung Cancer - Non Small Cell (NSCLC) Clinical Trial |
|
|
Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of PF02341066 versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK)gene Locus (A8081007)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Lung Cancer - Non Small Cell (NSCLC) Clinical Trial |
|
|
Phase 2, Open-Label Single Arm Study of the efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation of Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (A8081005)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
Lung Cancer - Non Small Cell (NSCLC) Clinical Trial |
|
|
A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer (E7389-G000-205)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
|
|
|
|
|
Lymphoma: Hodgkin Clinical Trial |
|
|
|
Lymphoma: Hodgkin Clinical Trial |
|
|
|
|
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With
Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
A Phase II, Multicenter, Single-Arm, Open-Label Study of Single-Agent Lenalidomide (Revlimid) in Patients with Mantle Cell non-Hodgkins Lymphoma who have relapsed after Bortezomib or are Refractory or Intolerant to Bortezmib (CC-5013-MCL-001)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (C05013)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment (OMB110918)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
A Phase II, Multicenter, Open-Label Study of YM155 Plus Rituximab in Previously Treated Subjects with CD20-Positive B-Cell Non-Hodgkin's Lymphoma Who are Ineligible for or Have Previously Received an Autologous Stem Cell Transplantation (155-CL-031)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
|
Lymphoma: Non-Hodgkin Clinical Trial |
|
|
|
|
|
|
|
|
Melanoma Clinical Trial |
|
|
|
Melanoma Clinical Trial |
|
|
|
|
|
|
|
|
Multisite Advanced Cancers (Phase I/II) Clinical Trial |
|
|
|
Multisite Advanced Cancers (Phase I/II) Clinical Trial |
|
|
|
Multisite Advanced Cancers (Phase I/II) Clinical Trial |
|
|
A Phase I Dose-Escalation Study of PHA-739358 Administered in Combination with Docetaxel or Gemcitabine or Bevacizumab in Adult Patients with Advanced Solid Tumors. (AURA-6202-008)
Phase
I
For more information call
(310)205-5707 or email us |
|
|
|
|
Multisite Advanced Cancers (Phase I/II) Clinical Trial |
|
|
A Phase I, Multicenter, Open Label, Dose Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily x 5 followed by a 21 day rest period in Patients with Advanced Solid Tumors (PRLX93936-0001)
Click Here for Full Protocol and Eligibility Criteria
Phase
I
For more information call
(310)205-5707 or email us |
|
|
|
|
Multisite Advanced Cancers (Phase I/II) Clinical Trial |
|
|
|
|
|
|
|
|
Myeloma Clinical Trial |
|
|
|
Myeloma Clinical Trial |
|
|
Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE® and Dexamethasone (VD) versus VELCADE®, Melphalan, and Prednisone (VMP)
Click Here for Full Protocol and Eligibility Criteria
Phase
IIIB
For more information call
(310)205-5707 or email us |
|
|
|
|
Myeloma Clinical Trial |
|
|
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma (PX-171-009)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Myeloma Clinical Trial |
|
|
|
|
|
|
|
|
Pancreatic Cancer Clinical Trial |
|
|
|
Pancreatic Cancer Clinical Trial |
|
|
|
|
|
|
|
|
Prostate Cancer Clinical Trial |
|
|
|
Prostate Cancer Clinical Trial |
|
|
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (CRPC2 AFFIRM MDV3100)
Click Here for Full Protocol and Eligibility Criteria
Phase
III
For more information call
(310)205-5707 or email us |
|
|
|
|
Prostate Cancer Clinical Trial |
|
|
|
|
|
|
|
|
Renal Cell Clinical Trial |
|
|
|
Renal Cell Clinical Trial |
|
|
An Open-Label, Single-Arm, Phase II Trial of IV BI6727 in Patients with Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy (1230.2)
Click Here for Full Protocol and Eligibility Criteria
Phase
II
For more information call
(310)205-5707 or email us |
|
|
|
|
|
|
|
|
 |
|
 |
